{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:41:17Z","timestamp":1773286877901,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2010]]},"DOI":"10.3109\/14653240903493417","type":"journal-article","created":{"date-parts":[[2010,1,18]],"date-time":"2010-01-18T06:54:04Z","timestamp":1263797644000},"page":"154-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["The immunosuppressive effect of Wharton's jelly stromal cells depends on the timing of their licensing and on lymphocyte activation"],"prefix":"10.1016","volume":"12","author":[{"given":"Erica","family":"Valencic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Piscianz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marino","family":"Andolina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Tommasini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3109\/14653240903493417_bib0005","first-page":"393","article-title":"The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells","volume":"3","author":"Friedenstein","year":"1970","journal-title":"Cell Tiss Kin"},{"key":"10.3109\/14653240903493417_bib0010","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1634\/stemcells.2007-0417","article-title":"Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells","volume":"25","author":"Can","year":"2007","journal-title":"Stem Cells"},{"key":"10.3109\/14653240903493417_bib0015","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1634\/stemcells.2004-0013","article-title":"Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord","volume":"22","author":"Wang","year":"2004","journal-title":"Stem Cells"},{"key":"10.3109\/14653240903493417_bib0020","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1634\/stemcells.2007-0439","article-title":"Wharton's jelly-derived cells are a primitive stromal cell population","volume":"26","author":"Troyer","year":"2008","journal-title":"Stem Cells"},{"key":"10.3109\/14653240903493417_bib0025","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/14653240500319234","article-title":"Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement","volume":"7","author":"Horwitz","year":"2005","journal-title":"Cytotherapy"},{"key":"10.3109\/14653240903493417_bib0030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"10.3109\/14653240903493417_bib0035","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1097\/TP.0b013e3181a28635","article-title":"Mesenchymal stem cells for therapeutic purposes","volume":"87","author":"Sensebe","year":"2009","journal-title":"Transplantation"},{"key":"10.3109\/14653240903493417_bib0040","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study","volume":"371","author":"Le Blanc","year":"2008","journal-title":"Lancet"},{"key":"10.3109\/14653240903493417_bib0045","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.tp.0000267918.07906.08","article-title":"Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G","volume":"84","author":"Nasef","year":"2007","journal-title":"Transplantation"},{"key":"10.3109\/14653240903493417_bib0050","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1634\/stemcells.2007-0554","article-title":"Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3 +regulatory T cells","volume":"26","author":"Selmani","year":"2008","journal-title":"Stem Cells"},{"key":"10.3109\/14653240903493417_bib0055","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1634\/stemcells.2007-0878","article-title":"Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens","volume":"26","author":"Morandi","year":"2008","journal-title":"Stem Cells"},{"key":"10.3109\/14653240903493417_bib0060","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/j.transproceed.2009.06.119","article-title":"Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function","volume":"41","author":"Renner","year":"2009","journal-title":"Transplant Proc"},{"key":"10.3109\/14653240903493417_bib0065","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1634\/stemcells.2006-0071","article-title":"Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma","volume":"24","author":"Chang","year":"2006","journal-title":"Stem Cells"},{"key":"10.3109\/14653240903493417_bib0070","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1365-2249.2007.03422.x","article-title":"Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells","volume":"149","author":"Ryan","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.3109\/14653240903493417_bib0075","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/MOT.0b013e328317a462","article-title":"Mesenchymal stem cell therapy for degenerative inflammatory disorders","volume":"13","author":"Muller","year":"2008","journal-title":"Curr Opin Organ Transplant"},{"key":"10.3109\/14653240903493417_bib0080","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cellimm.2009.06.010","article-title":"Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues","volume":"259","author":"Yoo","year":"2009","journal-title":"Cell Immunol"},{"key":"10.3109\/14653240903493417_bib0085","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1089\/ten.tea.2008.0630","article-title":"Requirement of IFN-gamma-mediated indoleamine 2,3 dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells","volume":"15","author":"Delarosa","year":"2009","journal-title":"Tissue Eng Part A"},{"key":"10.3109\/14653240903493417_bib0090","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1097\/TP.0b013e3181a2876f","article-title":"A role for mesenchymal stem cells in the control of graft-versus-host disease","volume":"87","author":"Cohen","year":"2009","journal-title":"Transplantation"},{"key":"10.3109\/14653240903493417_bib0095","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3324\/haematol.11869","article-title":"Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application","volume":"93","author":"Sessarego","year":"2008","journal-title":"Haematologica"},{"key":"10.3109\/14653240903493417_bib0100","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1634\/stemcells.2007-1028","article-title":"Immune properties of human umbilical cord Wharton's jelly-derived cells","volume":"26","author":"Weiss","year":"2008","journal-title":"Stem Cells"},{"key":"10.3109\/14653240903493417_bib0105","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3109\/14653240903079401","article-title":"Efficient expansion of mesenchymal stromal cells from umbilical cord under low serum conditions","volume":"11","author":"Girdlestone","year":"2009","journal-title":"Cytotherapy"},{"key":"10.3109\/14653240903493417_bib0110","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/rheumatology\/kel267","article-title":"Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and autoimmune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro","volume":"46","author":"Bocelli-Tyndall","year":"2007","journal-title":"Rheumatology"},{"key":"10.3109\/14653240903493417_bib0115","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cellimm.2008.04.009","article-title":"The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function","volume":"251","author":"Ramasamy","year":"2008","journal-title":"Cell Immunol"},{"key":"10.3109\/14653240903493417_bib0120","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1097\/TP.0b013e3181a285b0","article-title":"The immunosuppressive properties of mesenchymal stem cells","volume":"87","author":"Siegel","year":"2009","journal-title":"Transplantation"},{"key":"10.3109\/14653240903493417_bib0125","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1097\/01.tp.0000269199.16209.22","article-title":"Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes","volume":"84","author":"Belladonna","year":"2007","journal-title":"Transplantation"},{"key":"10.3109\/14653240903493417_bib0130","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1634\/stemcells.2005-0008","article-title":"Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells","volume":"24","author":"Krampera","year":"2006","journal-title":"Stem Cells"},{"key":"10.3109\/14653240903493417_bib0135","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3858\/emm.2009.41.5.035","article-title":"Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10","volume":"41","author":"Yang","year":"2009","journal-title":"Exp Mol Med"},{"key":"10.3109\/14653240903493417_bib0140","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/eji.200738129","article-title":"IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease","volume":"38","author":"Polchert","year":"2008","journal-title":"Eur J Immunol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324910703777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324910703777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:13:13Z","timestamp":1761430393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324910703777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"alternative-id":["S1465324910703777"],"URL":"https:\/\/doi.org\/10.3109\/14653240903493417","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2010]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The immunosuppressive effect of Wharton's jelly stromal cells depends on the timing of their licensing and on lymphocyte activation","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3109\/14653240903493417","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}